A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients
Completed
Abbott
Phase 3
2003-01-01
The purpose of the study was to determine the long-term effect of sibutramine treatment on
cardiovascular outcomes in overweight and obese patients at risk of a cardiovascular event.
A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety.
Completed
Abbott
Phase 3
2000-07-01
The purpose of this study is to assess the effectiveness of sibutramine on weight loss,
reduction in body size and improvement in metabolic risk factors and safety in obese
adolescents.
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
Completed
AstraZeneca
Phase 2
2006-11-01
This study will examine the safety, tolerability, and body weight effect of subcutaneous
pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or
phentermine in overweight and obese subjects.
A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder
Completed
Abbott
Phase 3
2000-08-01
The purpose of this study is to examine the safety and efficacy of sibutramine in preventing
binge eating episodes. Additionally the study aim is to evaluate the safety and efficacy of
sibutramine in reducing body weight in subjects with binge-eating disorder.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
